New pharma-led funding program for Canadian drug discovery research

Together with the Quebec Consortium for Drug Discovery (CQDM), Brain Canada is pleased to share an upcoming funding opportunity for Canadian researchers. CQDM’s Quantum Leap pharma-led funding program for drug discovery research aims to support innovative translational biopharmaceutical research projects that have the potential to improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs.

Projects selected as part of the Quantum Leap program focus on developing cutting-edge technologies with the potential to significantly advance the R&D activities of CQDM’s pharmaceutical members. Quantum Leap projects are executed in close collaboration and with the expert support and funds of pharmaceutical members.

Brain Canada is partnering with the Quantum Leap pharma-led funding program for drug discovery research on eligible brain related projects.

Please note: Budget structures can vary depending on each project, please contact CQDM to confirm eligibility before applying,

Please email appliquez-apply@cqdm.org

Funding for the Quantum Leap partnership has been made possible with the financial support of Health Canada, through the Canada Brain Research Fund, an innovative partnership between the Government of Canada (through Health Canada) and Brain Canada, and the CQDM.

Call for proposals are open year-round for Quantum Leap projects.

Deadline to participate in the next selection round: May 26th, 2021

Fore more information, please contact Jesse Paterson, Senior Director of Business Development at CQDM, at appliquez-apply@cqdm.org.